Experimental Autoimmune Myocarditis Group Research Articles

Immunoregulatory effects of α-GalCer in a murine model of autoimmune myocarditis

ObjectiveThis study was designed to investigate the immunoregulatory role of α-galactosylceramide (α-GalCer), a ligand for invariant natural killer T (iNKT) cells, on experimental autoimmune myocarditis (EAM) induced in Balb/c mice,...

Immunoregulatory effects of α-GalCer in a murine model of autoimmune myocarditis

This study was designed to investigate the role of α-galactosylceramide (α-GalCer) on experimental autoimmune myocarditis (EAM), and to explore the underlying mechanisms. Balb/c mice were immunized with porcine cardiac myosin to establish the EAM model. All the immunized mice were divided into two groups, the α-GalCer group and the EAM group. α-GalCer or vehicle was given intraperitoneally at the time of immunization. Then α-GalCer or PBS was injected on alternate days for 6 weeks. Myocardial inflammation was evaluated by H & E staining and the expression levels of C/EBPβ and α-SMA were determined by immunohistochemistry. CD4 +CD25 +Foxp3 + Tregs and iNKT cells were analyzed and sorted by flow cytometry. Western blot analysis was performed to detect MMP-2 and MMP-9 protein expression. Following α-GalCer treatment for 6 weeks, myocardial inflammation improved significantly in the α-GalCer treated group compared to the EAM group. The proportions of CD4 +CD25 +Foxp3 + regulatory T cells and NK1.1 + iNKT cells were statistically increased in the α-GalCer treated group compared to the EAM and normal control groups. In contrast to the EAM group, α-GalCer treatment significantly increased myocardial MMP-2 and MMP-9 expression. Expression of C/EBPβ increased significantly in the EAM group compared to the other two groups. In contrast, the expression of α-SMA did not differ significantly among the three groups. This study demonstrated that α-GalCer alleviates EAM. Thus, α-GalCer represents a potential therapeutic target for autoimmune-inflammation mediated cardiac damage. α-GalCer protects EAM through upregulation of the proportion of iNKT and Tregs and increased expression of myocardial MMP-2 and MMP-9.

Treatment and Prevention of Experimental Autoimmune Myocarditis with CD28 Superagonists

Objectives: Experimental autoimmune myocarditis (EAM), a rodent model of human dilated cardiomyopathy (DCM), is mediated by an autoimmune mechanism. We investigated whether a CD28 superagonistic antibody selectively targeting CD4+CD25+ regulatory T cells (T_regs) provides effective therapy for EAM. Methods: Four groups of 5 rats were used. The normal control group was immunized with PBS. The EAM group was immunized with porcine myosin. The experimental group was immunized with myosin and superagonistic CD28 antibody JJ316. The final group was immunized with myosin and an unrelated rat IgG. Autoantibody and IL-10 production, CD4+CD25+ cell levels, Foxp3 expression and cardiac histology were analyzed. Results: Anti-myosin autoantibody levels were higher in the EAM and isotype control groups than the normal control group (p < 0.05), and reduced in the CD28-JJ316 group (p < 0.05). The levels of CD25+CD4+ cells, IL-10 and splenocyte Foxp3 expression were significantly lower in the EAM and isotype control groups versus the CD28-JJ316 group (p < 0.05). Infiltration of inflammatory cells was observed in the EAM and isotype control groups, whereas CD28-JJ316 ameliorated myocarditis. Conclusion: CD28 superagonists could be effective in EAM treatment by up-regulating Foxp3 expression and contributing to CD4+CD25+ T_reg activation and expansion. The enhancement in IL-10 by CD28 superagonists also ameliorated the disease.

Change of cardiac function in experimental autoimmune myocarditis is correlated with the expression of annexin VI

Objective — The objective of this study was to investigate annexin VI expression in polypeptides induced experimental autoimmune myocarditis (EAM) in mice, and explore the relationship between the annexin VI and cardiac function at different periods of myocarditis.Methods and results — BALB/C mice were randomly divided into two main groups: control and polypeptides-induced EAM group; the PA and the PC groups represent the acute and the chronic phase of myocarditis in polypeptides-induced EAM group separately. Cardiac function was evaluated by haemodynamic measurement. Myocardial histopathological observation was performed to identify the degree of inflammation in EAM. Expression level and distribution of annexin VI were assessed by Western blotting and immunohistochemistry.We found that the polypeptides induced myocarditis and moderately severe cardiomyopathic changes. Only the PC group had significantly reduced haemodynamics. Expression levels of annexin VI decreased in the PA group and increased in the PC group.Conclusions — Annexin VI is down-regulated in the acute phase of EAM, and overexpressed in the chronic phase of EAM. Annexin VI may be responsible for the compensation and aggravation of cardiac function in different phases of EAM.

Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, are known to inhibit cholesterol biosynthesis and prevent inflammation and oxidative stress. To explore the effects of atorvastatin on inflammatory progression and major cardiac electrophysiological changes in myocarditis, we used an animal model of experimental autoimmune myocarditis (EAM). In this model, BALB/c mice were treated with atorvastatin and we evaluated the levels of inflammation markers and currents of ionic channels that contribute to the duration of action potential (APD) of ventricular myocytes. We demonstrated that atorvastatin treatment attenuated inflammatory infiltration and suppressed the increase in TNF-α and IFN-γ levels in EAM mouse hearts. In the whole-cell patch-clamp experiment, ventricular cardiomyocyte APD was prolonged in EAM group, and atorvastatin blocked this change. We further found that atorvastatin attenuated the significant decrease in outward potassium currents in EAM myocytes. Our results suggested that atorvastatin may ameliorate EAM progression by reducing inflammatory cytokine level. Atorvastatin exerted the antiarrhythmic effects by selectively affecting cardiomyocyte ion channel activity and therefore improves myocardial repolarization.

Electrical remodeling of the ventricular myocardium in myocarditis: studies of rat experimental autoimmune myocarditis.

The purpose of this study was to evaluate the electrical remodeling of the ventricular myocardium in the experimental autoimmune myocarditis (EAM) model in Lewis rats. EAM was induced by immunization with cardiac myosin. During the active myocarditis phase, the effective refractory period (ERP), the duration of the monophasic action potential (MAPD) was extracted from the left ventricular free wall, and the mRNA levels of Kv1.4, 4.2, 4.3 and L type Ca2+ channel were determined by RNase protection assays. The inducibility of ventricular arrhythmia was higher in EAM rats than in the control rat, and the direct relationship between the coupling intervals of the premature stimulus and the ventricular arrhythmia in EAM rats. The ERP was prolonged in EAM rats compared with the control group. The MAPDs determined as 20% and 90% repolarization time, were both longer in EAM rats than in the controls. The level of expression of Kv4.2 mRNA was reduced in EAM rats in comparison with the controls, whereas those of Kv1.4, 4.3 and the L type Ca2+ channel were unchanged. Ventricular vulnerability was higher in EAM rats than in the control rats, and some of the ventricular arrhythmias observed in the EAM group seemed to be based on triggered activity. The level of expression of Kv4.2 mRNA was significantly reduced, and this change was compatible with prolongation of the action potential duration.